TriangleNCT01853748 · OUTCOME
Median Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Reported every 3 weeks for the first 12 weeks, then every 9 weeks for the subsequent 39 weeks, then follow-up up to 5 years after completion of study treatment or until death, whichever occurs first.
What was measured
OS is evaluated in patients with Stage I HER2-positive breast cancer treated with trastuzumab emtansine
Groups in this outcome
Trastuzumab Emtansine (T-DM1)
T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks
Paclitaxel + Trastuzumab (TH)
paclitaxel 80 mg/m2 IV weekly and trastuzumab 4 mg/kg IV load, followed by 2 mg/kg IV weekly for 12 weeks, followed by trastuzumab 6 mg/kg IV every 3 weeks for 13 treatments
| Group | Source count |
|---|---|
| Trastuzumab Emtansine (T-DM1) | 383 |
| Paclitaxel + Trastuzumab (TH) | 114 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Trastuzumab Emtansine (T-DM1) | NA | Not reported | NA | NA | The cohorts have good overall survival outcome, and never reached the median survival. The overall survival rate at month 80, the longest follow up time of the cohort, is 98%. Therefore, the median survival and the corresponding 95% CI can not be estimated. |
| Paclitaxel + Trastuzumab (TH) | NA | Not reported | NA | NA | The cohorts have good overall survival outcome, and never reached the median survival. The overall survival rate at month 80, the longest follow up time of the cohort, is 98%. Therefore, the median survival and the corresponding 95% CI can not be estimated. |
Complete source fields
- classes
- categories
- measurements
- comment
- The cohorts have good overall survival outcome, and never reached the median survival. The overall survival rate at month 80, the longest follow up time of the cohort, is 98%. Therefore, the median survival and the corresponding 95% CI can not be estimated.
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- The cohorts have good overall survival outcome, and never reached the median survival. The overall survival rate at month 80, the longest follow up time of the cohort, is 98%. Therefore, the median survival and the corresponding 95% CI can not be estimated.
- group Id
- OG001
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 383
- group Id
- OG001
- value
- 114
- units
- Participants
- description
- OS is evaluated in patients with Stage I HER2-positive breast cancer treated with trastuzumab emtansine
- dispersion Type
- 95% Confidence Interval
- groups
- description
- T-DM1 3.6mg/kg every three weeks by IV for 17 doses for a total of 51 weeks
- id
- OG000
- title
- Trastuzumab Emtansine (T-DM1)
- description
- paclitaxel 80 mg/m2 IV weekly and trastuzumab 4 mg/kg IV load, followed by 2 mg/kg IV weekly for 12 weeks, followed by trastuzumab 6 mg/kg IV every 3 weeks for 13 treatments
- id
- OG001
- title
- Paclitaxel + Trastuzumab (TH)
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- Reported every 3 weeks for the first 12 weeks, then every 9 weeks for the subsequent 39 weeks, then follow-up up to 5 years after completion of study treatment or until death, whichever occurs first.
- title
- Median Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice